IL-33 Modulates HIF-1α Expression and Retinal Neovascularization Through the Activation of ERK1/2-CREB Signaling in Microglia
BACKGROUND: The retina is sensitive to oxygen levels, and retinal ischemia plays a crucial role in retinal neovascularization (NV). Retinal ischemia triggers activation, proliferation, and migration of microglia, which might contribute to the pathogenesis of retinal NV. Because IL-33 (interleukin-33) receptors are predominantly located in microglia, we investigated whether IL-33 modulates pro-angiogenic factors in retinal microglia during ischemic retinal diseases. METHODS: We used a murine model of oxygen-induced retinopathy, human retinal microvascular endothelial cells, and HMC3 cells to study the role of microglia-specific IL-33 signaling on retinal NV. Using 3′ mRNA sequencing and Western blotting, we examined the IL-33 signaling pathways that contribute to IL-33-induced HIF-1α (hypoxia-inducible factor-1 alpha) expression. RESULTS: The results demonstrated that IL-33 regulates microglia activation in the ischemic retina, and deletion of microglia along with IL-33 leads to a reduction in retinal NV. Our results from 3′ mRNA sequencing show that IL-33 promotes the expression of HIF-1α in microglia. In addition, IL-33 not only induces the expression of HIF-1α at both the mRNA and protein levels but also facilitates its nuclear translocation. We observed an increase in the migration and sprouting of human retinal microvascular endothelial cells after treatment with supernatant derived from human microglia exposed to IL-33. Our findings demonstrate that IL-33 modulates HIF-1α expression in microglia through ERK1/2 (extracellular signal-regulated kinase 1 and 2)–CREB (cAMP-responsive element-binding protein) signaling, which regulates retinal NV in the ischemic retina. CONCLUSIONS: The present findings highlight the significance of IL-33 in modulating HIF-1α expression in microglia, which is pivotal in proliferative retinopathies, and suggest the exploration of IL-33 antagonists as a potential therapeutic approach for retinal NV.
Authors
- Nikhlesh Kumar Singh (ORCID: https://orcid.org/0000-0002-3665-6023)
- Shivantika Bisen (ORCID: https://orcid.org/0009-0003-8922-0519)
- Geetika Kaur (ORCID: https://orcid.org/0000-0003-0988-4503)
- Anamika Sharma (ORCID: https://orcid.org/0009-0004-5069-1994)
- D. sharma (ORCID: https://orcid.org/0000-0002-1824-6995)
- Ashok Kumar
Institutions
- Johns Hopkins University (US)
- Wayne State University (US)
- Johns Hopkins Medicine (US)
Publication Details
- Journal
- Arteriosclerosis Thrombosis and Vascular Biology
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1161/atvbaha.126.325463
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00